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Life-altering biologic therapeutics are complex large mole-
cules which include hormones, growth factors, interferons,
vaccines, monoclonal antibodies, recombinant proteins
and others. The time, cost and risk for advancing a biolo-
gic through the pipeline comes at a steep price. It is esti-
mated that the development of a biologic therapeutic is as
high as US$1.2 billion [1] versus the cost of developing a
small molecule Innovator estimated at US$350 million [2].
Consequently, a common characteristic of most protein
therapeutics is the relatively high cost.
Brazil’s government is looking at measures to control
the rising cost of healthcare with expenditures of $491
bn BRL ($220 bn USD)[3], along with $49.6 bn BRL
($21.6 bn USD)[4] for pharmaceutical drugs and $5.35
BRL ($2.4 USD)[5] for biologics. Despite the rising cost
pressures, Alexandre Padilha, Minister of Health stated
in the February 2012 Focus Report that “Brazil firmly
believes in universal access and supports all initiatives
that promote universal healthcare”[6].
The growing demand of biologics is an added financial
stress on Brazil’s National Public Healthcare System
SUS (Sistema Único De Saude) which includes coverage
of drug cost. With patent expiry approaching for several
blockbuster biologics, Brazil is assessing multi-faceted
programs and partnerships that facilitate the introduc-
tion of biosimilar therapeutics. The government initia-
tive for the development of local biosimilars and
improvement of national biologics capabilities, attempts
to address cost savings measures to the healthcare sys-
tem while reducing the risk of supply associated with
imported branded biologics.
Through the coordination of the Ministry of Health
and private and public companies, the Partnership for
Productive Development (PDP) initiative was developed
for the local manufacturing of 14 biological drugs seven
of which are monoclonal antibodies (mAb)[7] that
involve facilities with greater complexity and unique
manufacturing processes.
The manufacturing process is important for all drugs,
but especially for biological medicines, which are more
complex structurally requiring a high degree of technol-
ogy and scientific expertise to stabilize the complex
molecular structures. These differences are important to
take into account when understanding how the manu-
facturing process for a biological medicine can have an
impact on product efficacy, quality and safety. Establish-
ing “biosimilarity” to a reference product for a biosimilar
drugs requires more preclinical and clinical testing than
is usually necessary for generic small-molecule drugs
because of the complexities of the molecular structure
and manufacturing process of biologics.
Biosimilar development is a high-risk activity demand-
ing significant resources with cost around US$75 - $250
million [8] versus the cost to develop a generic small
molecule (US$1 million [9] - $3.5 million [10]). Addition-
ally, building a biologics manufacturing facility is
expected to be in the range of up to US$400 million [11].
One option to mitigate the high cost and risk of develop-
ing and manufacturing biosimilars is to partner with
Contract Development and Manufacturing Organizations
(CDMO). CDMOs specializing in the manufacturing of
complex biologics can provide access to capacity with
lower risk and investment and apply their scientific and
technical expertise to serve as a strategic partner in the
development and manufacturing of biosimilars.
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